MedTrace Logo

Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors

NCT06301828 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-03-08

No results posted yet for this study

Summary

This is a single-arm, prospective, exploratory clinical study to evaluate the efficacy and safety of endostar combined with stereotactic body radiation therapy (SBRT) and Envafolimab in patients with advanced gastrointestinal cancer after multi-line treatment.

Conditions

  • Gastrointestinal Neoplasms

Interventions

DRUG

Envafolimab Injection

Endostar+SBRT+Envafolimab Injection

DRUG

Endostar

Endostar+SBRT+Envafolimab Injection

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • wei X wei, M.D. · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-21
Primary Completion
2025-06-21
Completion
2026-02-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06301828 on ClinicalTrials.gov